ARWR Dec 2024 22.000 call
| Previous close | 6.10 |
| Open | 6.10 |
| Bid | 5.30 |
| Ask | 8.50 |
| Strike | 22.00 |
| Expiry date | 2024-12-20 |
| Day's range | 6.10 - 6.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
Business WireArrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
PASADENA, Calif., May 02, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from
Business WireArrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif., April 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Business WireArrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
